Major Investor Insight Venture Partners Files to Sell Additional $10.4M in Hinge Health Stock
HNGE has more than doubled off its 52-week low of $30.08.
Summary
Major institutional investor Insight Venture Partners has filed to sell another $10.4 million in Hinge Health stock, extending a recent trend of significant share dispositions.
Key Events · Ownership and Investor Activity · HNGE
-
Intent to Sell Additional Shares
Insight Venture Partners, a 10% stockholder, has filed a Form 144 indicating its intent to sell 116,183 shares of Hinge Health Class A stock, valued at approximately $10.4 million.
-
Continuation of Selling Trend
This filing is part of an ongoing pattern of share distribution by Insight Venture Partners, which has sold over $17.9 million worth of shares in the past three months, and has filed multiple Form 144s recently.
-
Stock Trading Near 52-Week High
The proposed sale occurs while Hinge Health's stock is trading near its 52-week high of $90.91, potentially indicating the investor is locking in gains.
Analysis · HNGE · Technology
This Form 144 filing indicates Insight Venture Partners, a 10% stockholder, intends to sell an additional $10.4 million worth of Hinge Health stock. This continues a pattern of significant share distribution by this institutional investor, adding to the substantial sales observed over the past three months. The ongoing selling by a major holder, especially while the stock trades near its 52-week high, could create an overhang on the share price.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HNGE was trading at $89.30 on NYSE in the Technology sector, with a market capitalization of approximately $6.9B. The 52-week trading range was $30.08 to $90.91. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.